Today: 9 June 2026
Browse Category

NYSE:SMFG 16 October 2025 - 27 November 2025

Sumitomo Mitsui Financial Group (SMFG) Stock Rises as Japan’s Bank Rally Extends – November 27, 2025 Update

Sumitomo Mitsui Financial Group (SMFG) Stock Rises as Japan’s Bank Rally Extends – November 27, 2025 Update

Sumitomo Mitsui Financial Group shares closed at ¥4,684 in Tokyo on Thursday, up 2.2% with 2.8 million shares traded, extending a two-week rally. The Nikkei 225 surged above 50,300, led by bank and tech stocks. SMFG’s ADRs in New York ended Wednesday at $17.84, up 2.5%. No new company-specific filings were reported Thursday.
27 November 2025
···
Sumitomo Mitsui Financial Group (SMFG) Stock Today – November 26, 2025: Price Action, High-Dividend Buzz, Buyback Momentum and Outlook

Sumitomo Mitsui Financial Group (SMFG) Stock Today – November 26, 2025: Price Action, High-Dividend Buzz, Buyback Momentum and Outlook

Sumitomo Mitsui Financial Group ADRs closed at $17.40 in New York, up 1.5%, near a 52-week high and signaling a positive open for Tokyo shares. The ADR price implies a ¥68 gain over the last Tokyo close of ¥4,457. SMFG is highlighted in Japanese media as a top high-dividend stock, with a projected yield around 3.2–3.5% and five straight years of dividend increases.
26 November 2025
··
Jefferies Stock Rollercoaster: Earnings Beat, First Brands Fallout & Analyst Forecasts

Jefferies Stock Rollercoaster: Earnings Beat, First Brands Fallout & Analyst Forecasts

Jefferies Financial Group shares fell over 5% on Oct. 16 to their lowest level since June after news of shareholder lawsuits tied to its exposure to bankrupt First Brands Group. The stock is down about 25% in October and 37% year-to-date. Jefferies reported better-than-expected Q3 earnings, but costs surged nearly 20%. Japan’s SMBC is raising its stake to 20% in a $912 million deal announced last month.
16 October 2025
···

Stock Market Today

  • Evotec Shares Slide Amid Losses and Valuation Debate
    June 8, 2026, 10:00 PM EDT. Evotec (XTRA:EVT) shares dropped about 31% over the past year despite modest revenue growth and notable pharma partnerships. Trading near €4.93, the stock is about 28% undervalued versus a fair value estimate of €6.83 but remains unprofitable. Investors face a critical choice amid ongoing losses and reliance on future execution to boost margins and revenues. The biotech's shift to technology licensing and expanding pharma deals may enhance cash flow, yet risks include dependency on key clients and limited internal production capacity. Analysts caution that valuation hinges on the arrival of sustained profits. Prospective investors should evaluate these factors amid mixed market sentiment.

Latest articles

Chip Rally Breaks as Nasdaq Faces Tight Labor Market

Nasdaq rises after hours as chips recover

9 June 2026
Nasdaq jumped 0.86% as chip stocks rebounded, with Intel soaring 11.2% on news Google ordered over 3 million AI chips for 2028, while Apple slid 1.9% after unveiling new AI features. Investors await Wednesday’s May CPI inflation report, which could spark volatility in tech and growth stocks.
Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

9 June 2026
Broadcom shares jumped 2.8% to $396.60 as chip stocks rebounded after last week’s $1 trillion sector wipeout, but investors remain cautious after Broadcom’s Q2 revenue missed expectations and the company declined to raise its 2027 AI revenue forecast, fueling concerns that rapid AI growth may not meet Wall Street’s high demands.
BitMine Stock Gains as Ether Holdings Approach 5% Target

BitMine Stock Gains as Ether Holdings Approach 5% Target

9 June 2026
BitMine Immersion Technologies shares jumped 6% after revealing ether holdings climbed to 5.54 million tokens, now 4.59% of Ethereum’s supply, with $9.6 billion in crypto, cash and stakes. The company priced a $273.8 million preferred stock offering, with proceeds possibly funding more ETH purchases and staking. BitMine projects $230 million in annualized staking revenues but warns of risks if ETH or financing falters.
Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Go toTop